CME Group Q3FY26 Results: Earnings release and call set for Oct 21

scanx
Reviewed by
Naman SScanX News Team
Key Highlights
  • CME Group will announce Q3 2026 earnings before market open on October 21, 2026
  • Written highlights and press release scheduled for 6:00 am Central Time
  • Investor conference call begins at 7:30 am Central Time with executive Q&A
  • Telephone dial-in available with passcode 1944793
powered bylight_fuzz_icon
50093724

*this image is generated using AI for illustrative purposes only.

CME Group Inc. will announce its third-quarter 2026 earnings results before the markets open on Wednesday, October 21, 2026. The global derivatives marketplace will provide written highlights and a press release at 6:00 am Central Time.

An investor conference call featuring company executives will follow at 7:30 am Central Time. Participants can access a live audio webcast via the Investor Relations section of the company’s website. An archived recording will be available shortly after the event concludes.

Conference Call Details

Investors wishing to listen via telephone can dial 877-918-3040 from within the United States or +1 312-470-7282 from outside the country. Calls must be placed at least 10 minutes before the start time. The participant passcode for both lines is 1944793.

About CME Group

CME Group operates as the world’s leading derivatives marketplace. It enables clients to trade futures, options, cash, and OTC markets across major asset classes including interest rates, equity indexes, foreign exchange, cryptocurrencies, energy, agricultural products, and metals.

The company facilitates trading through platforms such as CME Globex for futures and options on futures, BrokerTec for fixed income, and EBS for foreign exchange. It also operates CME Clearing, one of the world’s leading central counterparty clearing providers.

How might CME Group's Q3 2026 earnings reflect the impact of recent regulatory changes on cryptocurrency and energy derivatives trading volumes?

Will management provide updated guidance on the adoption rates of new digital asset products in response to evolving institutional demand?

How is CME Clearing positioning itself to manage counterparty risk amid potential volatility in global interest rate markets for the remainder of 2026?

like19
dislike

CME Group plans E-mini equity factor futures launch on Sept. 21

scanx
Reviewed by
Ritika DScanX News Team
Key Highlights
  • CME Group plans to launch E-mini Equity Factor futures on September 21
  • The launch is pending final regulatory review
  • This expands CME Group's equity product suite
  • No specific contract details were disclosed yet
powered bylight_fuzz_icon
49377874

*this image is generated using AI for illustrative purposes only.

CME Group plans to launch E-mini Equity Factor futures on September 21, pending regulatory review. The move expands the world’s leading derivatives marketplace’s equity product suite.

The Chicago-based exchange stated the new contracts will be added to its existing offerings, subject to final regulatory approval. No specific details regarding contract specifications or initial trading volumes were disclosed in the announcement.

Product Expansion

The introduction of these factor-based futures represents a strategic addition to CME Group’s equity derivatives lineup. By launching E-mini versions, the exchange likely aims to provide accessible exposure to specific equity factors for a broader range of investors.

Regulatory clearance remains the final hurdle before the September 21 start date. Until then, market participants await further technical specifications and trading rules.

Which specific equity factors (e.g., value, momentum, quality) will these new E-mini futures target, and how might this influence factor rotation strategies?

How will the introduction of CME's factor futures impact trading volumes and liquidity in existing ETFs or single-stock options that currently serve as proxies for these factors?

What potential regulatory concerns regarding market manipulation or concentration risk could delay the final approval beyond the September 21 target date?

like17
dislike

More News on CME Group Inc